Cargando…

Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study

Involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT, i.e., visfatin or pre-B-cell colony-enhancing factor), a cancer metabokine, in chronically hepatitis C virus (HCV)-infected (CHC) patients with sustained virological responses (SVRs) remains elusive. This 8-year prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ming-Ling, Lin, Yu-Sheng, Chang, Ming-Yu, Hsu, Chia-Lin, Chien, Rong-Nan, Fann, Cathy SJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834047/
https://www.ncbi.nlm.nih.gov/pubmed/33446046
http://dx.doi.org/10.1080/21505594.2020.1870080
_version_ 1783642197371912192
author Chang, Ming-Ling
Lin, Yu-Sheng
Chang, Ming-Yu
Hsu, Chia-Lin
Chien, Rong-Nan
Fann, Cathy SJ
author_facet Chang, Ming-Ling
Lin, Yu-Sheng
Chang, Ming-Yu
Hsu, Chia-Lin
Chien, Rong-Nan
Fann, Cathy SJ
author_sort Chang, Ming-Ling
collection PubMed
description Involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT, i.e., visfatin or pre-B-cell colony-enhancing factor), a cancer metabokine, in chronically hepatitis C virus (HCV)-infected (CHC) patients with sustained virological responses (SVRs) remains elusive. This 8-year prospective cohort study evaluated eNAMPT profiles of 842 consecutive CHC patients, including 519 who had completed an anti-HCV therapy course and pre-therapy and 24-week post-therapy surveys. For 842 patients, pre-therapy associations were HCV RNA, homeostatic model assessment for insulin resistance (HOMA-IR) index, and body mass index with eNAMPT levels, and NAMPT-rs61330082 T allele with total cholesterol levels. NAMPT-rs10953502, NAMPT-rs2058539, and NAMPT-rs61330082 were in a linkage disequilibrium block, which was associated with total cholesterol levels. Compared to pre-therapy levels, at 24 weeks post-therapy, decreased eNAMPT and increased lipid levels were observed in SVR patients (n = 427). Among SVR patients, higher cumulative incidences of cardiovascular events occurred in those with a NAMPT-rs61330082 TT genotype than those with non-TT genotypes (28.2% vs. 8.4%, p < 0.001). NAMPT-rs61330082 TT genotype was independently associated with incident cardiovascular events (95% CI hazard ratio (HR): 1.88–10.37; HR: 4.415); no eNAMPT profiles were associated with incident malignancies. Of CHC patients, hepatic vascular endothelial cells and baseline peripheral leukocytes expressed higher eNAMPT levels than controls, and peripheral eNAMPT-positive leukocyte proportions decreased after SVR. During HCV infection, eNAMPT involvement in glucose metabolism was modulated by HCV RNA linked to lipid metabolism and NAMPT-associated SNPs. Hepatic endothelial cells and peripheral leukocytes potentially secrete eNAMPT. Caution is required for incident cardiovascular events in SVR patients with NAMPT-rs61330082 TT genotype.
format Online
Article
Text
id pubmed-7834047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78340472021-02-02 Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study Chang, Ming-Ling Lin, Yu-Sheng Chang, Ming-Yu Hsu, Chia-Lin Chien, Rong-Nan Fann, Cathy SJ Virulence Research Paper Involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT, i.e., visfatin or pre-B-cell colony-enhancing factor), a cancer metabokine, in chronically hepatitis C virus (HCV)-infected (CHC) patients with sustained virological responses (SVRs) remains elusive. This 8-year prospective cohort study evaluated eNAMPT profiles of 842 consecutive CHC patients, including 519 who had completed an anti-HCV therapy course and pre-therapy and 24-week post-therapy surveys. For 842 patients, pre-therapy associations were HCV RNA, homeostatic model assessment for insulin resistance (HOMA-IR) index, and body mass index with eNAMPT levels, and NAMPT-rs61330082 T allele with total cholesterol levels. NAMPT-rs10953502, NAMPT-rs2058539, and NAMPT-rs61330082 were in a linkage disequilibrium block, which was associated with total cholesterol levels. Compared to pre-therapy levels, at 24 weeks post-therapy, decreased eNAMPT and increased lipid levels were observed in SVR patients (n = 427). Among SVR patients, higher cumulative incidences of cardiovascular events occurred in those with a NAMPT-rs61330082 TT genotype than those with non-TT genotypes (28.2% vs. 8.4%, p < 0.001). NAMPT-rs61330082 TT genotype was independently associated with incident cardiovascular events (95% CI hazard ratio (HR): 1.88–10.37; HR: 4.415); no eNAMPT profiles were associated with incident malignancies. Of CHC patients, hepatic vascular endothelial cells and baseline peripheral leukocytes expressed higher eNAMPT levels than controls, and peripheral eNAMPT-positive leukocyte proportions decreased after SVR. During HCV infection, eNAMPT involvement in glucose metabolism was modulated by HCV RNA linked to lipid metabolism and NAMPT-associated SNPs. Hepatic endothelial cells and peripheral leukocytes potentially secrete eNAMPT. Caution is required for incident cardiovascular events in SVR patients with NAMPT-rs61330082 TT genotype. Taylor & Francis 2021-01-15 /pmc/articles/PMC7834047/ /pubmed/33446046 http://dx.doi.org/10.1080/21505594.2020.1870080 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Chang, Ming-Ling
Lin, Yu-Sheng
Chang, Ming-Yu
Hsu, Chia-Lin
Chien, Rong-Nan
Fann, Cathy SJ
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
title Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
title_full Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
title_fullStr Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
title_full_unstemmed Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
title_short Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
title_sort accelerated cardiovascular risk after viral clearance in hepatitis c patients with the nampt-rs61330082 tt genotype: an 8-year prospective cohort study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834047/
https://www.ncbi.nlm.nih.gov/pubmed/33446046
http://dx.doi.org/10.1080/21505594.2020.1870080
work_keys_str_mv AT changmingling acceleratedcardiovascularriskafterviralclearanceinhepatitiscpatientswiththenamptrs61330082ttgenotypean8yearprospectivecohortstudy
AT linyusheng acceleratedcardiovascularriskafterviralclearanceinhepatitiscpatientswiththenamptrs61330082ttgenotypean8yearprospectivecohortstudy
AT changmingyu acceleratedcardiovascularriskafterviralclearanceinhepatitiscpatientswiththenamptrs61330082ttgenotypean8yearprospectivecohortstudy
AT hsuchialin acceleratedcardiovascularriskafterviralclearanceinhepatitiscpatientswiththenamptrs61330082ttgenotypean8yearprospectivecohortstudy
AT chienrongnan acceleratedcardiovascularriskafterviralclearanceinhepatitiscpatientswiththenamptrs61330082ttgenotypean8yearprospectivecohortstudy
AT fanncathysj acceleratedcardiovascularriskafterviralclearanceinhepatitiscpatientswiththenamptrs61330082ttgenotypean8yearprospectivecohortstudy